Cargando…
Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran
INTRODUCTION: Patient registries play an important role in obtaining real-world evidence of the cost-effectiveness of treatments. However, their implementation is costly and sometimes infeasible in many middle-income countries (MICs). We explored the combination of data-mining and a large claims dat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166984/ https://www.ncbi.nlm.nih.gov/pubmed/30273393 http://dx.doi.org/10.1371/journal.pone.0205079 |
_version_ | 1783360124915548160 |
---|---|
author | Ansaripour, Amir Zendehdel, Kazem Tadayon, Niki Sadeghi, Fatemeh Uyl-de Groot, Carin A. Redekop, W. Ken |
author_facet | Ansaripour, Amir Zendehdel, Kazem Tadayon, Niki Sadeghi, Fatemeh Uyl-de Groot, Carin A. Redekop, W. Ken |
author_sort | Ansaripour, Amir |
collection | PubMed |
description | INTRODUCTION: Patient registries play an important role in obtaining real-world evidence of the cost-effectiveness of treatments. However, their implementation is costly and sometimes infeasible in many middle-income countries (MICs). We explored the combination of data-mining and a large claims database to estimate the direct healthcare costs of HER2-positive breast cancer (BC) treatment in Iran and the fraction of total costs from trastuzumab use. METHOD: We performed a retrospective analysis of claims data from the Iran Social Security Organization, a health insurer which covers approximately 50%(~40 million) of the Iranian population, in the period of 21/03/2011-20/03/2014. A data-mining algorithm using R software and validated using patient dossiers in the Cancer Research Center identified 1295 patients and divided them into the three main HER2-positive breast cancer stages (early, loco-regional and advanced). A payer perspective was used to calculate the absolute and relative direct costs of healthcare services associated with the treatment of HER2-positive breast cancer in the public and private healthcare systems. RESULTS: The number of women totaled 802 (early), 125 (loco-regional) and 218 (advanced). The mean age[SD] was 45[10], 46[10] and 48[10] years, respectively, while mean follow-up in all stages was approximately one year. Average costs of direct healthcare care in early, loco-regional and advanced stages were €11,796 (95%CI: €9,356-€12,498), €8,253 (95%CI: €6,843-€10,002), and €17,742 (95%CI: €15,720-€19,505), respectively. Trastuzumab accounted for the largest share of total costs in all three stages (range: 53–76%). CONCLUSION: Wherever comprehensive patient registries are infeasible or costly, real-world costs can be estimated through claims databases and data-mining strategies. Using this method, real-world costs have been estimated in Iran. The stage-specific cost estimates derived from this study can be used to perform real-world cost-effectiveness analyses of therapies for HER2-positive BC and support healthcare financing decisions. |
format | Online Article Text |
id | pubmed-6166984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-61669842018-10-19 Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran Ansaripour, Amir Zendehdel, Kazem Tadayon, Niki Sadeghi, Fatemeh Uyl-de Groot, Carin A. Redekop, W. Ken PLoS One Research Article INTRODUCTION: Patient registries play an important role in obtaining real-world evidence of the cost-effectiveness of treatments. However, their implementation is costly and sometimes infeasible in many middle-income countries (MICs). We explored the combination of data-mining and a large claims database to estimate the direct healthcare costs of HER2-positive breast cancer (BC) treatment in Iran and the fraction of total costs from trastuzumab use. METHOD: We performed a retrospective analysis of claims data from the Iran Social Security Organization, a health insurer which covers approximately 50%(~40 million) of the Iranian population, in the period of 21/03/2011-20/03/2014. A data-mining algorithm using R software and validated using patient dossiers in the Cancer Research Center identified 1295 patients and divided them into the three main HER2-positive breast cancer stages (early, loco-regional and advanced). A payer perspective was used to calculate the absolute and relative direct costs of healthcare services associated with the treatment of HER2-positive breast cancer in the public and private healthcare systems. RESULTS: The number of women totaled 802 (early), 125 (loco-regional) and 218 (advanced). The mean age[SD] was 45[10], 46[10] and 48[10] years, respectively, while mean follow-up in all stages was approximately one year. Average costs of direct healthcare care in early, loco-regional and advanced stages were €11,796 (95%CI: €9,356-€12,498), €8,253 (95%CI: €6,843-€10,002), and €17,742 (95%CI: €15,720-€19,505), respectively. Trastuzumab accounted for the largest share of total costs in all three stages (range: 53–76%). CONCLUSION: Wherever comprehensive patient registries are infeasible or costly, real-world costs can be estimated through claims databases and data-mining strategies. Using this method, real-world costs have been estimated in Iran. The stage-specific cost estimates derived from this study can be used to perform real-world cost-effectiveness analyses of therapies for HER2-positive BC and support healthcare financing decisions. Public Library of Science 2018-10-01 /pmc/articles/PMC6166984/ /pubmed/30273393 http://dx.doi.org/10.1371/journal.pone.0205079 Text en © 2018 Ansaripour et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Ansaripour, Amir Zendehdel, Kazem Tadayon, Niki Sadeghi, Fatemeh Uyl-de Groot, Carin A. Redekop, W. Ken Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran |
title | Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran |
title_full | Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran |
title_fullStr | Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran |
title_full_unstemmed | Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran |
title_short | Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran |
title_sort | use of data-mining to support real-world cost analyses: an example using her2-positive breast cancer in iran |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166984/ https://www.ncbi.nlm.nih.gov/pubmed/30273393 http://dx.doi.org/10.1371/journal.pone.0205079 |
work_keys_str_mv | AT ansaripouramir useofdataminingtosupportrealworldcostanalysesanexampleusingher2positivebreastcanceriniran AT zendehdelkazem useofdataminingtosupportrealworldcostanalysesanexampleusingher2positivebreastcanceriniran AT tadayonniki useofdataminingtosupportrealworldcostanalysesanexampleusingher2positivebreastcanceriniran AT sadeghifatemeh useofdataminingtosupportrealworldcostanalysesanexampleusingher2positivebreastcanceriniran AT uyldegrootcarina useofdataminingtosupportrealworldcostanalysesanexampleusingher2positivebreastcanceriniran AT redekopwken useofdataminingtosupportrealworldcostanalysesanexampleusingher2positivebreastcanceriniran |